The use of ultrasonography, transient elastography, APRI and FIB-4 to Measure Liver steatosis and fibrosis in HIV-positive patients not co- infected with hepatitis viruses with hypertransaminasemia of unknown etiology on HAART

Open Infectious Diseases Journal

Volumn 5, Issue 1, 2011, Pages 1-5

  Izzo, Ilaria ^a   Biasi, Luciano ^a   Mendeni, Monia ^a   Prestini, Katiela ^a   Vavassori, Andrea ^a   Focà, Emanuele ^a   Quiros Roldan, Eugenia ^a   Carosi, Giampiero ^a   Torti, Carlo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Fibrosis; HIV infection; Hypertransaminasemia; Steatosis

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALCOHOL; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ALCOHOL BLOOD LEVEL; ANAMNESIS; APRI SCORE; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE SEVERITY; ECHOGRAPHY; EXPLORATORY RESEARCH; FATTY LIVER; FEMALE; FIB4 SCORE; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; LIVER FIBROSIS; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; SCORING SYSTEM; ULTRASONIC TRANSIENT ELASTOGRAPHY;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 80052249022     PISSN: None     EISSN: 18742793     Source Type: Journal    
DOI: 10.2174/1874279301105010001     Document Type: Article

References (28)

1. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22: 1-13.
2. Sulkowski M, Mehta S, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19: 585-592.
3. McGovern B, Ditelberg J, Taylor L, Gandhi R, Christopoulos K, Chapman S. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43: 365-372.
4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
5. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457.
6. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-78.
7. Cozzi Lepri A, Prosperi M, Lo Caputo S, et al. Fib4 is an independent predictor of serious liver disease among HIV-infected patients with or without HBV/HCV co-infection in the Icona foundation study. Italian Conference on AIDS and Retroviruses Brescia, Italy. 20-22 June 2010. Infection, 2010; 38 (Suppl 1): 73.
8. DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V 3rd. Prevalence and risk factor for significant liver fibrosis among HIVmonoinfected patients. BMC Infect Dis. 2010 May 13; 10: 116.
9. th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 16-19; San Francisco, USA [abstract 681].
10. Wai CT, Greenson JK, Fontana RJ, et al. A simple non invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
11. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis inpatients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
12. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46(3): 912-21.
13. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 32: 32-36.
14. Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol 2008; 32 (6 Suppl 1): 52-7.
15. González Guilabert MI, Hinojosa Mena-Bernal C, del Pozo González J, del Pozo Pérez MA. Retrospective study of FibroScan, APRI, FIB-4 and FORNS indexes compared with liver biopsy in the evaluation of liver fibrosis in patients with chronic hepatitis C monoinfection and HIV coinfection. Gastroenterol Hepatol 2010; 33(6): 425-32.
16. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
17. Mohammed SS, Aghdassi E, Salit IE, et al. HIV-positive patients with non-alcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr 2007; 45: 432-8.
18. Moreno-Torres A, Domingo P, Pujol J, Blanco-Vaca F, Arroyo JA, Sambeat MA. Liver trygliceride content in HIV-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy. Antivir Ther 2007; 12: 195-203.
19. Sutinen J, Häkkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002; 16: 2183-93.
20. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patient referred to a metabolic clinic: prevalence, characteristics, and predictors. CID 2008: 47; 250-257.
21. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference with non-alcoholic fatty liver disease. Gastroenterology 2006; 130: 2023-2030.
22. Torti C, Costarelli S, De Silvestri A, et al. Analysis of severe hepatic events associated with nevirapine-containing regimens. Drug Safety 2007; 30(12): 1161-1169.
23. Macìas J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 19(6): 767-74.
24. Berenguer J, Bellòn JM, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C coinfection. Clin Infect Dis 2008; 46(1): 137-43.
25. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44(1 Suppl): S132-9.
26. Mendes-Correa MC, Andrade Jr HF, Takakura CF, Seixas-Duarte MI. Hepatic ultrastructural mithocondrial changes prior to antiretroviral therapy in HIV-infected patients in Brazil. J Intern Ass Ph AIDS Care 2008; 7 (5): 252-58.
27. Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenter and Hepat 2008; 6: 1167-1169.
28. Maida I, Garcia-Gasco P, Sotgiu G, Rios MJ, Vispo ME, Martin-Carbonero L. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13(1): 103-107.